Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;104:234-239

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gazmuri, R. J.
Right arrow Articles by Kolarova, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gazmuri, R. J.
Right arrow Articles by Kolarova, J. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*LACTIC ACID
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow CPR and emergency cardiac care
Right arrow Animal models of human disease
Right arrow Arrythmias-basic studies
Right arrow Ischemic biology - basic studies

(Circulation. 2001;104:234.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Successful Ventricular Defibrillation by the Selective Sodium-Hydrogen Exchanger Isoform-1 Inhibitor Cariporide

Raúl J. Gazmuri, MD, PhD; Iyad M. Ayoub, MS; Elizabeth Hoffner, MS; Julieta D. Kolarova, MD

From the Medical Service, Section of Critical Care Medicine, North Chicago VA Medical Center (R.J.G., I.M.A., E.H., J.D.K.), and Department of Medicine, Division of Critical Care Medicine, Finch University of Health Sciences/The Chicago Medical School (R.J.G.), North Chicago, Ill.

Correspondence to Raúl J. Gazmuri, MD, PhD, Medical Service (111F), North Chicago VA Medical Center, 3001 Green Bay Rd, North Chicago, IL 60064. E-mail raul.gazmuri{at}med.va.gov


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background— Sodium-hydrogen exchanger isoform-1 (NHE-1) activation worsens functional myocardial abnormalities associated with ischemia and reperfusion. We hypothesize that these abnormalities may limit cardiac resuscitation from ventricular fibrillation (VF) and investigated whether NHE-1 inhibition with the benzoylguanidine derivative cariporide could improve resuscitability, postresuscitation myocardial function, and short-term survival in isolated heart and intact rat models of VF.

Methods and Results— In the isolated rat heart, VF was induced for 25 minutes. Perfusion was interrupted for the initial 10 minutes and restarted at 10% of baseline flow for the remaining 15 minutes (simulating chest compression). Cariporide ameliorated ischemic contracture, prevented postresuscitation diastolic dysfunction, and favored earlier return of contractile function. In the intact rat, cariporide, injected into the right atrium before chest compression was started (after 6 minutes of untreated VF), prompted spontaneous defibrillation between minutes 7 and 9 of chest compression in 6 of 8 rats. In contrast, electrical defibrillation was required in each of 8 control rats after completion of a predetermined 16-minute interval of VF. After resuscitation, cariporide-treated rats had less ventricular ectopic activity and normalized their hemodynamic function faster. Electrical defibrillation was then timed in control rats to match the time when spontaneous defibrillation occurred in cariporide-treated rats. With comparable VF duration, postresuscitation hemodynamic dysfunction was ameliorated by cariporide, but only when more severe ischemia was modeled by prolongation of the interval of untreated VF from 6 to 10 minutes.

Conclusion— NHE-1 inhibition may represent a novel and remarkably effective intervention for resuscitation from VF.


Key Words: cardiopulmonary resuscitation • fibrillation • ischemia • sodium-hydrogen antiporter • cariporide


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The likelihood of successful resuscitation from out-of-hospital ventricular fibrillation (VF) is disappointingly low. Poor outcome reflects in part limitations imposed by myocardial abnormalities that develop during VF as a result of ischemia and reperfusion. These abnormalities include ischemic contracture,1,2 decreased myocardial responsiveness to electrical defibrillation,3 postresuscitation ventricular ectopic activity,4 and postresuscitation myocardial dysfunction.5

Multiple mechanisms of cell injury unleashed during ischemia and reperfusion may contribute to these abnormalities. One important mechanism involves activation of pathways that increase sarcolemmal Na+ influx with subsequent intracellular Na+ accumulation.6 Among these pathways, the sarcolemmal Na+-H+ exchanger isoform-1 (NHE-1) seems to play an important role. It is likely that NHE-1 is activated as a result of the intense myocardial acidosis that develops during cardiac arrest and that its activity is further enhanced by the accompanying neuroendocrine stress response. Stimulation of {alpha}1-adrenergic,7 endothelin-1,8 and angiotensin II9 receptors have been shown to increase the sensitivity of the NHE-1 "H+ sensor" by activation of phospholipase C and subsequent NHE-1 phosphorylation.10 In addition, ischemia and reperfusion generate hydrogen peroxide11 and lysophosphatidylcholine,12 which may also activate NHE-1.

We hypothesized that NHE-1 inhibition may represent a novel approach for cardiac resuscitation and used isolated heart and intact rat models of VF to test the hypothesis that NHE-1 inhibition improves resuscitability, ameliorates postresuscitation myocardial dysfunction, and increases short-term survival.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The studies were approved by our Research and Development Committee and were conducted in accordance with institutional guidelines.

Isolated Rat Heart
A model of VF and ischemia previously developed in adult Sprague-Dawley rats was used.13,14 Hearts were harvested from 511- to 642-g rats according to the classic Langendorff technique, except that perfusion was started in situ (to minimize preconditioning) with a bicarbonate-buffered solution containing (in mmol/L) NaCl 118, KCl 4.7, CaCl2 1.25, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2, glucose 5, and Na pyruvate 2 and equilibrated with 95% oxygen (PO2 523±23 mm Hg) and 5% CO2 (PCO2 30±2 mm Hg; pH 7.48±0.04). A latex balloon with an unstressed volume of {approx}500 µL was positioned in the left ventricle. A thermistor (TSD102A, BIOPAC Systems, Inc) and an electrode (to induce VF) were advanced into the right ventricle. The heart was immersed in a water-circulated chamber filled with perfusate, and the myocardial temperature was maintained at 37±0.3°C. After stabilization, the perfusate flow was increased to 20 mL/min, and the balloon was distended to an end-diastolic pressure of 10 mm Hg.

End-diastolic pressure-volume curves were obtained by 20-µL balloon decrements from an end-diastolic pressure >50 mm Hg to an end-diastolic pressure <10 mm Hg. The residual balloon volume was added to obtain absolute values, and the data were fitted to a 3-constant exponential function by the nonlinear Levenberg-Marquardt method according to the equation P(V)=Axe{alpha}xV+C, in which P(V) is pressure as a function of volume, {alpha} is the slope of this relationship, and A and C are parameters of the equation. By use of the fitted equation, volumes corresponding to arbitrarily selected end-diastolic pressures ranging from 15 to 50 mm Hg were obtained. With this approach, the data variability was limited to the volume axis, facilitating statistical analysis and graphic rendition. Coronary vascular resistance corresponded to the mean perfusion pressure divided by the perfusate flow. Left ventricular water content was determined from wet and dry weights.14

VF was induced by a 0.5-mA alternating current delivered for 3 minutes to the right ventricular endocardium. Additional 30-second intervals of current were delivered whenever spontaneous defibrillation occurred, securing a 25-minute interval of uninterrupted VF. The perfusate flow was stopped during the initial 10 minutes (simulating untreated VF) and resumed at 10% of baseline flow for the remaining 15 minutes (simulating chest compression). The perfusate flow was then increased to baseline levels, and defibrillation was attempted with 0.1-J monophasic epicardial shocks delivered at 1-minute intervals.

The selective and potent NHE-1 inhibitor cariporide (4-isopropyl-methylsulfonylbenzoyl-guanidine methanesulfonate, Aventis Pharma Deutschland GmbH) was administered during the interval of low-flow perfusion and the initial 5 minutes after defibrillation (n=8). A 100-µmol/L solution prepared in 0.9% NaCl was infused into the aortic cannula at 10% of the perfusate flow to yield a 10-µmol/L concentration in the coronary circuit. This concentration was shown to fully inhibit the exchanger in rat cardiac myocytes without effects on the Na+-Ca2+ exchanger and fast Na+ current and to cause negligible effects on noninactivating Na+ currents.15 Control hearts received 0.9% NaCl (n=8).

Intact Rat
Adult Sprague-Dawley rats (438 to 545 g) were anesthetized by intraperitoneal injection of sodium pentobarbital (45 mg/kg) supplemented with 10 mg/kg at 30-minute intervals. Core temperature was maintained between 36.5°C and 37.5°C by use of an infrared heating lamp. A 5F catheter was orally advanced into the trachea and used subsequently for mechanical ventilation. Placement was verified with an infrared CO2 analyzer (CO2SMO model 7100, Novametrix Medical Systems, Inc). PE50 catheters were advanced into the abdominal aorta and the right atrium for pressure measurements and blood sampling. Through the right jugular vein, a 3F catheter (C-PUM-301J, Cook) was advanced into the right atrium, and a precurved guidewire was advanced through its lumen into the right ventricle. It was subsequently used to induce VF.

Ventricular ectopic activity was analyzed during the initial 4 minutes after resuscitation. Premature wide-QRS complexes were classified as singlets, bigemini, salvos, and nonsustained wide-complex tachycardia defined as >=4 consecutive complexes lasting <=120 seconds. Coronary perfusion pressure corresponded to the aortic minus the right atrial pressure at the end of diastole during spontaneous circulation and at the end of chest relaxation during chest compression.

VF was induced by a 60-Hz alternating current delivered to the right ventricular endocardium (0.10 to 0.70 mA) for 3 minutes.16 Fifteen seconds before completion of a predetermined interval of untreated VF, a 1-mg/kg bolus of cariporide or 0.9% NaCl solution (control) was injected into the right atrium. The dose was chosen because it significantly reduced the incidence of ventricular arrhythmias after coronary occlusion and reperfusion in rats without adverse effects on heart rate, blood pressure, and QT interval.17 Positive pressure ventilation with 100% oxygen was then initiated with a pneumatic valve (R-481, Clippard Instrument Laboratory Inc) set to deliver 0.39 mL/100 g body wt at 100 breaths per minute. Concomitant chest compression was provided with a pneumatically driven compressor (CJ-80623, CJ Enterprises) synchronized to delivered 2 compressions per 1 breath (200 compressions per minute). The depth of compression was adjusted to promote a coronary perfusion pressure exceeding the 20 mm Hg threshold required for successful resuscitation.16,18 The maximum piston travel provided estimates of compression depth. At a predetermined interval, electrical defibrillation was attempted by a maximum of two 2-J DC monophasic transthoracic countershocks (Lifepak 9P, Physio-Control). If VF persisted or an organized electric rhythm with a mean arterial pressure of <=25 mm Hg ensued, chest compression was resumed for 30 seconds. The defibrillation-compression sequence was repeated for a maximum of 3 additional cycles, increasing the energy of individual shocks to 4 and then to 8 J for the last 2 cycles. After successful resuscitation, ventilation was continued with a volume-controlled ventilator (683, Harvard Apparatus) using 100% oxygen for the initial 15 minutes and 50% oxygen for the remaining interval.

Three series of 16 experiments each (8 cariporide and 8 controls) were conducted. In the first series, VF remained untreated for 6 minutes, and electrical defibrillation was attempted after an additional 10 minutes of chest compression. Because spontaneous defibrillation occurred in cariporide-treated rats (shortening the duration of VF), 2 additional series were conducted in which electrical defibrillation was timed in control rats to match the time of spontaneous defibrillation in cariporide-treated rats. For these 2 series, the dose of cariporide was increased to 3 mg/kg, the interval of untreated VF corresponded to 6 and 10 minutes, and the postresuscitation interval was increased to 180 minutes.

Statistical Analysis
Continuous variables were analyzed between groups by 1-way or 2-way ANOVA. Categorical variables were analyzed by Fisher’s exact test. Equivalent nonparametric tests were substituted when tests for normality or equal variance failed. Multiple regression was used to assess the effects of drug treatment and other intervening variables on selected postresuscitation outcomes. The data are presented as mean±SD unless otherwise stated. A value of P<0.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Isolated Rat Heart
Ischemic contracture developed during the 15-minute interval of low-flow perfusion and VF, increasing the ventricular pressure by 24±11 mm Hg in control hearts but only by 9±5 mm Hg (P<0.005) in cariporide-treated hearts (Figure 1, bottom). Cariporide also attenuated increases in coronary vascular resistance (Figure 1, top). After resuscitation, hearts treated with cariporide had normal end-diastolic pressure-volume relationships (Figure 2) despite no effects on left ventricular water content (83.3±0.6% in control hearts versus 82.9±0.6% in cariporide-treated hearts, P=NS). In addition, contractile function normalized earlier in hearts treated with cariporide (Figure 3).



View larger version (24K):
[in this window]
[in a new window]
 
Figure 1. Isolated perfused heart. Solid bars represent perfusate flow, duration of VF, and duration of cariporide or NaCl infusion. LVP indicates left ventricular end-diastolic pressure during sinus rhythm and "arrest" pressure during VF; CVR, coronary vascular resistance. Values are mean±SEM. indicates NaCl (n=8); {circ}, cariporide (n=8). Differences in LVP and CVR between treatment groups were significant (P<0.0001 by 2-way ANOVA for treatment effect). *P<0.05, {dagger}P<0.01, {ddagger}P<0.001 vs NaCl by 1-way ANOVA.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 2. Left ventricular end-diastolic pressure (LVEDP)–volume (LVEDV) curves. Circles indicate baseline; squares, 10 minutes postresuscitation; and triangles, 30 minutes postresuscitation. Solid symbols represent NaCl (n=8); open symbols, cariporide (n=8). Values are mean±SEM. *P<0.05 vs baseline curves by 2-way repeated-measures ANOVA for time effect; {dagger}P<0.00001 vs corresponding curve in hearts treated with cariporide by 2-way ANOVA for treatment effect.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 3. Maximal rate of left ventricular pressure rise (+dP/dtmax). BL indicates baseline; PR, postresuscitation. Solid bars represent NaCl (n=8); open bars, cariporide (n=8). *P<0.05 vs BL within each group by 1-way repeated-measures ANOVA.

Intact Rat
First Series (6 Minutes Untreated VF, Unmatched Defibrillation)
During VF, the depth of chest compression necessary to attain comparable coronary perfusion pressure was less in cariporide-treated rats (Table 1). Unexpectedly, spontaneous defibrillation with return of a perfusing rhythm occurred between minutes 7 and 9 of chest compression in 6 of 8 rats treated with cariporide but in none of 8 controls. A representative experiment is shown in Figure 4. Spontaneous defibrillation was associated with restoration of spontaneous circulation 145 seconds earlier and the need for fewer electrical shocks with less cumulative energy (Table 1). After restoration of spontaneous circulation, cariporide-treated rats had less ventricular ectopic activity (Table 2), higher mean aortic pressure, and more rapidly normalized arrest-induced increases in arterial lactate (Figure 5). Each cariporide-treated rat survived 120 minutes, whereas 3 control rats died displaying progressive hypotension.


View this table:
[in this window]
[in a new window]
 
Table 1. Resuscitation Effort in the Intact Rat



View larger version (34K):
[in this window]
[in a new window]
 
Figure 4. Intact rat experiment demonstrating spontaneous defibrillation. LV indicates left ventricular pressure; Ao, aortic pressure; RA, right atrial pressure; and EKG, ECG. A bolus of cariporide was injected into right atrium after 5 minutes and 45 seconds of untreated VF. Chest compression (CC) was started after 6 minutes of untreated VF. Spontaneous defibrillation occurred during minute 8 of CC, with rapid return to baseline (BL) hemodynamic conditions. Artifacts caused by CC were removed from VF signal with a high-pass digital filter (10-Hz cutoff frequency).


View this table:
[in this window]
[in a new window]
 
Table 2. Postresuscitation Ventricular Ectopic Activity



View larger version (45K):
[in this window]
[in a new window]
 
Figure 5. Intact rat resuscitation. First series (6 minutes untreated VF, unmatched defibrillation times). MAP indicates mean aortic pressure; PETCO2, end-tidal PCO2. Solid bars represent fraction of inspired oxygen (FiO2), maximally allowed duration of VF, and maximally allowed duration of chest compression (CC). indicates NaCl (n=8); {circ}, cariporide (n=8). Numbers in brackets denote animals that received cariporide but had not spontaneously converted VF into a perfusing rhythm during chest compression. Surviving animals are denoted in parentheses. Values are mean±SEM. *P<0.05 vs NaCl by 1-way ANOVA.

Second Series (6 Minutes Untreated VF, Matched Defibrillation)
As in the preceding series, a lesser depth of chest compression and spontaneous defibrillation were observed in cariporide-treated rats (Table 1). Despite matched defibrillation times, cariporide-treated rats restored spontaneous circulation 28 seconds earlier (P=NS) because no additional defibrillation-compression cycles were required (Table 1). Again, less postresuscitation ventricular ectopic activity occurred in cariporide-treated rats (Table 2). In contrast to the preceding series, indices of hemodynamic function were not different between the 2 groups (Figure 6). Seven cariporide-treated rats and 6 control rats survived the postresuscitation interval.



View larger version (43K):
[in this window]
[in a new window]
 
Figure 6. Intact rat. Second series (6 minutes untreated VF, matched defibrillation times). Symbols and abbreviations as in Figure 5.

Third Series (10 Minutes Untreated VF, Matched Defibrillation)
As in the 2 preceding series, spontaneous defibrillation occurred only in cariporide-treated rats. This again prompted fewer electrical shocks and return of spontaneous circulation 29 seconds earlier (P=NS) (Table 1). Postresuscitation ventricular ectopic activity was not statistically different except for fewer salvos (Table 2). In contrast to the preceding series, however, cariporide was associated with significantly higher mean aortic pressure during the initial 30 minutes after resuscitation. In addition, the end-tidal PCO2 was higher at 5 minutes and from 120 to 180 minutes after resuscitation (Figure 7). Seven cariporide-treated rats survived the postresuscitation interval. Of the 8 control rats, 7 were successfully resuscitated, but only 4 survived the postresuscitation interval.



View larger version (48K):
[in this window]
[in a new window]
 
Figure 7. Intact rat. Third series (10 minutes untreated VF, matched defibrillation times). Symbols and abbreviations as in Figure 5. *P<0.05,{dagger}P<0.01 vs NaCl by 1-way ANOVA.

When all 3 series combined were considered, more cariporide-treated rats were alive at the completion of the postresuscitation interval (22 of 24 versus 15 of 24; P<0.05).

Multiple regression models were developed to assess the effects of drug treatment, number of shocks, the total energy delivered, and the time to restoration of spontaneous circulation on various postresuscitation outcomes by use of the combined data from the 2 series with matched defibrillation times (Table 3). Cariporide had a significant predictive effect on mean aortic pressure, singlets, bigemini, and salvos, whereas the total amount of energy delivered was the only predictor of postresuscitation ventricular tachycardia. The number of shocks contributed to the incidence of singlets, and the time to restoration of spontaneous circulation contributed to the mean aortic pressure and bigemini.


View this table:
[in this window]
[in a new window]
 
Table 3. Multiple Regression Models


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
There is compelling evidence that NHE-1 inhibition ameliorates the severity of regional and global myocardial ischemia in the quiescent (nonfibrillating) heart.19 The role of NHE-1 inhibition when VF accompanies ischemia, however, is unclear. Although VF may worsen ischemia by intensifying the myocardial energy requirements,13 VF may also promote additional Na+ influx,20 potentially circumventing the benefits associated with NHE-1 inhibition. In previous studies using an isolated rat heart preparation, we documented intramyocardial Na+ increases from 11.5±0.8 (baseline) to 15.1±1.7 mmol/kg wet tissue after 25 minutes of ischemia in the absence of VF and to 20.2±2.1 mmol/kg in the presence of VF.21 Interventions limiting sarcolemmal Na+ entry (cariporide and/or perfusion with HEPES-substituted buffer) reduced intracellular Na+ to 17.6±2.3 mmol/kg and attenuated the development of ischemic contracture by a magnitude comparable to that observed in the present experiments.

In the present studies, we demonstrate that NHE-1 inhibition in the setting of VF-induced cardiac arrest ameliorates myocardial abnormalities previously shown to compromise resuscitability and survival.

Ischemic Contracture
Development of ischemic contracture has been documented in intact porcine models of VF2 and in patients suffering out-of-hospital cardiac arrest.1 Ischemic contracture limits the left ventricular filling volumes, causing progressive reductions in stroke volume and coronary perfusion pressure and ultimately compromising resuscitability. In the isolated heart, cariporide markedly attenuated the magnitude of ischemic contracture and lessened the increases in coronary vascular resistance. In the intact rat, the depth of compression necessary to achieve comparable hemodynamic effects averaged 12% less in cariporide-treated rats. This effect is consistent with attenuation of ischemic contracture, allowing larger ventricular volumes to be maintained before each chest compression. It also suggests that increasing the depth of compression after administration of cariporide could result in larger systemic blood flows.

Spontaneous Defibrillation
Small hearts have a tendency to spontaneously defibrillate. Sustained VF, however, can be induced after 3 minutes of uninterrupted electrical stimulation in both the isolated13 and the intact16 rat heart. Subsequent defibrillation typically requires restoration of coronary perfusion and electrical shocks. In the present intact rat experiments, however, cariporide promoted spontaneous defibrillation in 70% of the instances after {approx}8 minutes of chest compression, hence obviating the need for electrical shocks. It is likely that spontaneous defibrillation was the result of a metabolic rather than hemodynamic effect, because the end-tidal PCO2 and the coronary perfusion pressure (surrogate measurements of systemic and coronary blood flow)18 were comparable in control and cariporide-treated rats. Additional work is necessary to elucidate the mechanisms of spontaneous defibrillation and to determine whether this effect could lower the energy requirements for successful electrical defibrillation in larger animals that do not autodefibrillate.

Postresuscitation Ectopic Activity
Significantly less ventricular ectopic activity occurred in cariporide-treated rats. The multiple regression analyses identified cariporide as the main factor responsible for the decreased incidence of singlets, bigemini, and salvos. The smaller number of episodes of ventricular tachycardia was probably related to the lower energy delivered as a result of spontaneous defibrillation.

Reperfusion arrhythmias have been linked to Ca2+ overload and cytosolic Ca2+ oscillations.22 Thus, amelioration of reperfusion arrhythmias after administration of cariporide is consistent with the postulated mechanism of NHE-1 inhibition; namely, reduction in Na+-induced cytosolic Ca2+ overload. Consistent with these observations, pretreatment with cariporide has been shown to prevent the development of VF and other ventricular ectopic rhythms in rats after coronary artery ligation.23

Postresuscitation Myocardial Dysfunction
In the isolated heart, cariporide prevented postresuscitation diastolic dysfunction and prompted earlier return of contractile function. In the first intact rat series, cariporide was associated with improved postresuscitation hemodynamic function and faster normalization of arrest-induced lactate increases. No postresuscitation benefits were observed in the second series, however, when the defibrillation times were matched despite a slightly earlier return of spontaneous circulation ({approx}30 seconds) and fewer electrical shocks. Yet, when the duration of untreated VF was increased to 10 minutes, causing more severe postresuscitation hemodynamic dysfunction, cariporide had a beneficial effect manifested by a significantly higher mean aortic pressure during the initial 30 minutes after resuscitation. This effect, however, did not influence postresuscitation lactate changes, suggesting that the differences observed in the first series reflected the longer duration of cardiac arrest in control rats.

The multiple regression analyses identified drug effect and the time to restoration of spontaneous circulation as significant determinants of postresuscitation hemodynamic function. Postresuscitation hemodynamic benefits could have derived from preservation of diastolic function and faster recovery of systolic function, as suggested by the studies in the isolated rat heart preparation. Improved hemodynamic stability was associated with significant increases in survival.

Clinical Relevance
The effects of cariporide were examined in adult rats only; however, the cellular effects associated with NHE-1 activation may not be subject to large interspecies and age variation. Similar benefits, including improved myocardial function, preservation of cellular ultrastructure, and reduced incidence of arrhythmias after NHE-1 inhibition, have been confirmed in different experimental models and different species.24

In clinical settings, electrical defibrillation is typically attempted earlier after onset of VF. Yet, previous experiments in dogs25 and more recent clinical data26 suggest that efforts to improve the myocardial metabolic conditions before delivering electrical shocks may be warranted in instances of prolonged untreated VF. Our experimental protocols were designed to best characterize the myocardial effects of cariporide and therefore purposely planned electrical defibrillation 10 minutes after administration of cariporide. Although spontaneous defibrillation occurred after {approx}8 minutes, clinical protocols would most likely include earlier defibrillation attempts. Currently, some patients are successfully resuscitated within 5 to 10 minutes of advanced cardiac life support, yet many others require multiple electrical shocks and continued resuscitation efforts exceeding 10 minutes. For these patients, interventions that ameliorate the ischemic process, like the one proposed here, may be instrumental to securing successful resuscitation.


*    Acknowledgments
 
This study was supported in part by a VA Merit Review Grant entitled "Myocardial Protection During Cardiac Arrest." The authors wish to thank Mark Cohen, PhD, from the Naval Dental Research Institute, Great Lakes, Ill, for his assistance with the statistical analysis.

Received November 17, 2000; revision received March 14, 2001; accepted March 24, 2001.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Takino M, Okada Y. Firm myocardium in cardiopulmonary resuscitation. Resuscitation. 1996; 33: 101–106.[Medline] [Order article via Infotrieve]
  2. Klouche K, Weil MH, Sun S, et al. Echo-Doppler observations during cardiac arrest and cardiopulmonary resuscitation. Crit Care Med. 2000; 28: N212–N213.[Medline] [Order article via Infotrieve]
  3. Yakaitis RW, Ewy GA, Otto CW, et al. Influence of time and therapy on ventricular defibrillation in dogs. Crit Care Med. 1980; 8: 157–163.[Medline] [Order article via Infotrieve]
  4. Callaham M, Braun O, Valentine W, et al. Prehospital cardiac arrest treated by urban first-responders: profile of patient response and prediction of outcome by ventricular fibrillation waveform. Ann Emerg Med. 1993; 22: 1664–1677.[Medline] [Order article via Infotrieve]
  5. Gazmuri RJ, Weil MH, Bisera J, et al. Myocardial dysfunction after successful resuscitation from cardiac arreSt. Crit Care Med. 1996; 24: 992–1000.[Medline] [Order article via Infotrieve]
  6. Imahashi K, Kusuoka H, Hashimoto K, et al. Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res. 1999; 84: 1401–1406.[Abstract/Free Full Text]
  7. Yasutake M, Avkiran M. Exacerbation of reperfusion arrhythmias by alpha 1 adrenergic stimulation: a potential role for receptor mediated activation of sarcolemmal sodium-hydrogen exchange. Cardiovasc Res. 1995; 29: 222–230.[Medline] [Order article via Infotrieve]
  8. Khandoudi N, Ho J, Karmazyn M. Role of Na+-H+ exchange in mediating effects of endothelin-1 on normal and ischemic/reperfused hearts. Circ Res. 1994; 75: 369–378.[Abstract/Free Full Text]
  9. Matsui H, Barry WH, Livsey C, et al. Angiotensin II stimulates sodium-hydrogen exchange in adult rabbit ventricular myocytes. Cardiovasc Res. 1995; 29: 215–221.[Medline] [Order article via Infotrieve]
  10. Bianchini L, Pouyssegus J. Regulation of the Na+/H+ exchanger isoform NHE1: role of phosphorylation. Kidney Int. 1996; 49: 1038–1041.[Medline] [Order article via Infotrieve]
  11. Sabri A, Byron KL, Samarel AM, et al. Hydrogen peroxide activates mitogen-activated protein kinases and Na+-H+ exchange in neonatal rat cardiac myocytes. Circ Res. 1998; 82: 1053–1062.[Abstract/Free Full Text]
  12. Hoque AN, Haist JV, Karmazyn M. Na+-H+ exchange inhibition protects against mechanical, ultrastructural, and biochemical impairment induced by low concentrations of lysophosphatidylcholine in isolated rat hearts. Circ Res. 1997; 80: 95–102.[Abstract/Free Full Text]
  13. Gazmuri RJ, Berkowitz M, Cajigas H. Myocardial effects of ventricular fibrillation in the isolated rat heart. Crit Care Med. 1999; 27: 1542–1550.[Medline] [Order article via Infotrieve]
  14. Gazmuri RJ, Deshmukh S, Shah PR. Myocardial effects of repeated electrical defibrillations in the isolated fibrillating rat heart. Crit Care Med. 2000; 28: 2690–2696.[Medline] [Order article via Infotrieve]
  15. Scholz W, Albus U, Counillon L, Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res. 1995; 29: 260–268.[Medline] [Order article via Infotrieve]
  16. von Planta I, Weil MH, von Planta M, et al. Cardiopulmonary resuscitation in the rat. J Appl Physiol. 1988; 65: 2641–2647.[Abstract/Free Full Text]
  17. Xue YX, Aye NN, Hashimoto K. et al. Antiarrhythmic effects of HOE642, a novel Na+-H+ exchange inhibitor, on ventricular arrhythmias in animal hearts. Eur J Pharmacol. 1996; 317: 309–316.[Medline] [Order article via Infotrieve]
  18. Duggal C, Weil MH, Gazmuri RJ, et al. Regional blood flow during closed-chest cardiac resuscitation in rats. J Appl Physiol. 1993; 74: 147–152.[Abstract/Free Full Text]
  19. Karmazyn M, Gan XT, Humphreys RA, et al. The myocardial Na+-H+ exchange: structure, regulation, and its role in heart disease. Circ Res. 1999; 85: 777–786.[Abstract/Free Full Text]
  20. Pike MM, Luo CS, Yanagida S, et al. 23Na and 31P nuclear magnetic resonance studies in ischemia-induced ventricular fibrillation: alterations of intracellular Na+ and cellular energy. Circ Res. 1995; 77: 394–406.[Abstract/Free Full Text]
  21. Gazmuri RJ, Hoffner E, Kalcheim J, et al. Myocardial protection during ventricular fibrillation by reduction of proton-driven sarcolemmal sodium influx. J Lab Clin Med. 2001; 137: 43–55.[Medline] [Order article via Infotrieve]
  22. Lakatta EG, Guarnieri T. Spontaneous myocardial calcium oscillations: are they linked to ventricular fibrillation? J Cardiovasc Electrophysiol. 1993; 4: 473–489.[Medline] [Order article via Infotrieve]
  23. Humphreys RA, Haist JV, Chakrabarti S, et al. Orally administered NHE1 inhibitor cariporide reduces acute responses to coronary occlusion and reperfusion. Am J Physiol. 1999; 276: H749–H757.
  24. Karmazyn M. Mechanisms of protection of the ischemic and reperfused myocardium by sodium-hydrogen exchange inhibition. J Thromb Thrombolysis. 1999; 8: 33–38.[Medline] [Order article via Infotrieve]
  25. Niemann JT, Cairns CB, Sharma J, et al. Treatment of prolonged ventricular fibrillation: immediate countershock versus high-dose epinephrine and CPR preceding countershock. Circulation. 1992; 85: 281–287.[Abstract/Free Full Text]
  26. Cobb LA, Fahrenbruch CE, Walsh TR, et al. Influence of cardiopulmonary resuscitation prior to defibrillation in patients with out-of-hospital ventricular fibrillation. JAMA. 1999; 281: 1182–1188.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
S. Wang, J. Radhakrishnan, I. M. Ayoub, J. D. Kolarova, D. M. Taglieri, and R. J. Gazmuri
Limiting sarcolemmal Na+ entry during resuscitation from ventricular fibrillation prevents excess mitochondrial Ca2+ accumulation and attenuates myocardial injury
J Appl Physiol, July 1, 2007; 103(1): 55 - 65.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. Kolarova, I. M. Ayoub, and R. J. Gazmuri
Cariporide enables hemodynamically more effective chest compression by leftward shift of its flow-depth relationship
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2904 - H2911.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. Kolarova, Z. Yi, I. M. Ayoub, and R. J. Gazmuri
Cariporide Potentiates the Effects of Epinephrine and Vasopressin by Nonvascular Mechanisms During Closed-Chest Resuscitation
Chest, April 1, 2005; 127(4): 1327 - 1334.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. M. Stevens, M. Salik Jahania, R. M. Mentzer Jr, and R. D. Lasley
Sodium-hydrogen exchange inhibition attenuates in vivo porcine myocardial stunning
Ann. Thorac. Surg., February 1, 2004; 77(2): 651 - 657.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. G. Rabkin, S. E. Cabreriza, F. H. Cheema, A. A. Hill, L. J. Curtis, R. R. Sciacca, R. S. Mosca, and H. M. Spotnitz
Cariporide is cardioprotective after iatrogenic ventricular fibrillation in the intact swine heart
Ann. Thorac. Surg., October 1, 2003; 76(4): 1264 - 1269.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. G. Rabkin, S. E. Cabreriza, J. C. LaCorte, A. D. Weinberg, L. Coku, R. Walsh, R. Mosca, and H. M. Spotnitz
Sodium-hydrogen exchange inhibition preserves ventricular function after ventricular fibrillation in the intact swine heart
J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1499 - 1509.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. M. Ayoub, J. Kolarova, Z. Yi, A. Trevedi, H. Deshmukh, D. L. Lubell, M. R. Franz, F. A. Maldonado, and R. J. Gazmuri
Sodium-Hydrogen Exchange Inhibition During Ventricular Fibrillation: Beneficial Effects on Ischemic Contracture, Action Potential Duration, Reperfusion Arrhythmias, Myocardial Function, and Resuscitability
Circulation, April 8, 2003; 107(13): 1804 - 1809.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S.-r. Wann, M. H. Weil, S. Sun, W. Tang, and T. Yu
Cariporide for Pharmacologic Defibrillation After Prolonged Cardiac Arrest
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2002; 7(3): 161 - 169.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
K. Shinagawa, H. Mitamura, S. Ogawa, and S. Nattel
Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling
Cardiovasc Res, May 1, 2002; 54(2): 438 - 446.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gazmuri, R. J.
Right arrow Articles by Kolarova, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gazmuri, R. J.
Right arrow Articles by Kolarova, J. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*LACTIC ACID
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow CPR and emergency cardiac care
Right arrow Animal models of human disease
Right arrow Arrythmias-basic studies
Right arrow Ischemic biology - basic studies